SCHEMBL30660320

SCHEMBL30660320

COc1ccc(NC(=O)c2cc(C(F)(F)F)ncc2Nc2ccc(F)c(F)c2CCCNC(=O)OC(C)(C)C)c(Br)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 2/20 0.35
▸ TGFBR1 P36897 2/20 0.35
▸ ACVR1B P36896 1/20 0.35
▸ ACVRL1 P37023 1/20 0.35
▸ KDR P35968 2/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ NTRK1 P04629 1/20 0.32
▸ ITK Q08881 3/20 0.32
▸ EGFR P00533 2/20 0.32
▸ SCN9A Q15858 2/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ SCN5A Q14524 1/20 0.31
▸ PTGES O14684 1/20 0.31
▸ GPR6 P46095 1/20 0.31
▸ BRD4 O60885 4/20 0.31
▸ NR1H2 P55055 1/20 0.31
▸ NR1H3 Q13133 1/20 0.31
▸ MAPK3 P27361 1/20 0.31
▸ FLT1 P17948 1/20 0.31
▸ CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30660266 0.89 SORT1 (0.36) STING1TGFBR1ACVR1BACVRL1KDR
SCHEMBL30660531 0.88 AXL (0.34) STING1TGFBR1ACVR1BACVRL1JAK2
SCHEMBL30660386 0.84 ACVR1B (0.38) STING1TGFBR1ACVR1BACVRL1KDR
SCHEMBL26944617 0.84 ACVR1B (0.38) STING1TGFBR1ACVR1BACVRL1KDR
SCHEMBL26931044 0.84 ACVR1B (0.39) STING1TGFBR1ACVR1BACVRL1KDR
SCHEMBL26931219 0.81 SORT1 (0.40) NTRK1
SCHEMBL24552895 0.80 DHODH (0.37) JAK2GPR6CYP2C9
SCHEMBL30824154 0.80 DHODH (0.37) JAK2GPR6CYP2C9
SCHEMBL24549979 0.75 LMNA (0.39) JAK2GPR6
SCHEMBL26944555 0.75 SORT1 (0.36) STING1NTRK1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368647-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-12-04 — — US disclosed
EP-4536660-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2025-04-16 — — EP disclosed
WO-2023238065-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368647-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN2A, SCN5A STING1 3862/4885TGFBR1 4590/4885ACVR1B 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback